Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05962021
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-01
First Post:
2023-07-10
Brief Title:
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
Neoadjuvant Toripalimab Plus Chemotherapy for Resectable Stage II-IIIB Non-squamous Non-small Cell Lung Cancer With EGFR Mutation a Multicentre Multi-cohort Exploratory Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab anti-PD1 plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation and to explore the potential predictive and prognostic biomarkers aiming to provide more abundant evidences for the preoperative treatment decision of non-squamous NSCLC patients
Detailed Description:
Previous studies have confirmed the efficacy of neoadjuvant immunotherapy in NSCLC patients without driver gene mutation while its efficacy in driver gene mutated patients is still controversial This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab anti-PD1 plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation and to explore the potential predictive and prognostic biomarkers aiming to provide more abundant evidences for the preoperative treatment decision of non-squamous NSCLC patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None